Relmada Therapeutics Taps Uro-Oncology Veteran as CBO to Drive NDV-01 Commercialization
Event summary
- Relmada Therapeutics appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer on July 28, 2026.
- Dalmia brings nearly three decades of experience in uro-oncology and corporate strategy, including leadership roles at Ferring Pharmaceuticals.
- He will lead Relmada's corporate strategy, commercial planning, and business development for NDV-01, its novel sustained-release intravesical therapy for NMIBC.
The big picture
Relmada Therapeutics is positioning itself for late-stage development of its lead candidate, NDV-01, by bringing in a seasoned executive with deep uro-oncology expertise. The appointment underscores the company's shift toward commercialization and strategic value creation, reflecting broader trends in biotech where specialized leadership is critical for navigating complex regulatory and market landscapes.
What we're watching
- Commercialization Strategy
- How Dalmia's experience with Ferring Pharmaceuticals' ADSTILADRIN will shape Relmada's approach to NDV-01's market entry.
- Business Development
- Whether Dalmia can leverage his M&A and licensing expertise to secure strategic partnerships for Relmada.
- Clinical Progress
- The pace at which NDV-01 advances through late-stage development under Dalmia's leadership.
Related topics